Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.

CONCLUSIONS: Combined treatment with glibenclamide and CoCl(2) inhibits TA2 spontaneous breast cancer growth and invasiveness with effects similar to paclitaxel.
PMID: 23714264 [PubMed - indexed for MEDLINE]

Source: Clinical Breast Cancer - December 22, 2013 Category: Cancer & Oncology Authors: Rong Z, Li L, Fei F, Luo L, Qu Y Tags: J Exp Clin Cancer Res Source Type: research